

Jeeyun Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2172793/publications.pdf>

Version: 2024-02-01

400
papers

17,161
citations

29994

54
h-index

20307

116
g-index

409
all docs

409
docs citations

409
times ranked

20620
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. <i>Gut</i> , 2022, 71, 676-685.	6.1	21
2	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. <i>European Radiology</i> , 2022, 32, 1-11.	2.3	6
3	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	6.1	23
4	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	1.2	5
5	Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. <i>Cancer Research and Treatment</i> , 2022, 54, 894-906.	1.3	6
6	A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology. <i>Molecular Cancer</i> , 2022, 21, 9.	7.9	2
7	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	1.3	13
8	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
9	Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial. <i>Journal of Cancer</i> , 2022, 13, 1097-1102.	1.2	2
10	Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. <i>Cancer Research and Treatment</i> , 2022, 54, 1240-1255.	1.3	4
11	Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1â€“positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 243-243.	0.8	8
12	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2â€“positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2022, 40, 242-242.	0.8	5
13	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	0.8	17
14	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	3.2	74
15	Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 551-551.	0.8	0
16	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	7
17	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
18	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Early Tumor Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	7.7	52
20	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
21	Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 1393-1408.	1.4	0
22	Abstract 6352: Ascites derived exosomes promote progression of advanced gastric cancers. <i>Cancer Research</i> , 2022, 82, 6352-6352.	0.4	0
23	Prevalence of MET aberration using next generation sequencing in oncology clinic: A real-world experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16099-e16099.	0.8	0
24	Comprehensive landscape of tumor angiogenesis via integrating RNA sequencing and three-dimensional microphysiological system.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16058-e16058.	0.8	1
25	Immune landscape of colorectal cancer lung metastasis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15542-e15542.	0.8	1
26	Solid tumor patients with G12V and G13D <i>KRAS</i> aberrations have poor survival following ICI treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14567-e14567.	0.8	0
27	Landscape of tumor mutation burden and correlation to clinical outcomes in 1,744 solid cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2667-2667.	0.8	0
28	Exosome in ascites can be a potential therapeutic target for gastric cancer with malignant ascites.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15008-e15008.	0.8	0
29	Oxaliplatin (3 months vs 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. <i>Journal of Clinical Oncology</i> , 2022, 40, 3868-3877.	0.8	6
30	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4045-4045.	0.8	0
31	Tumor microenvironment (TME) dynamics following capecitabine/oxaliplatin (CapeOx) plus pembrolizumab in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4053-4053.	0.8	0
32	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab ± Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	3.2	35
33	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021, 24, 457-466.	2.7	34
34	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1593-1603.	2.0	32
35	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	0.9	6
36	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021, 12, 460-466.	1.2	4

#	ARTICLE	IF	CITATIONS
37	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. <i>Journal of Cancer</i> , 2021, 12, 5681-5686.	1.2	0
38	Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. <i>Nature Communications</i> , 2021, 12, 975.	5.8	26
39	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	3.0	12
40	Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center. <i>Journal of Dermatology</i> , 2021, 48, 979-988.	0.6	2
41	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	7.7	105
42	Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3536-3536.	0.8	5
43	<i>ARAF</i> mutations confer resistance to the <i>RAF</i> inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	13.7	64
44	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	3.2	54
45	Contextualizing a single-arm trial of ceralasertib (cer) plus paclitaxel with real-world data (RWD) in patients (pts) with advanced melanoma previously treated with anti-PD-(L)1(PDx) therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21542-e21542.	0.8	0
46	Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9514-9514.	0.8	4
47	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. <i>Cancers</i> , 2021, 13, 2316.	1.7	5
48	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	3.4	184
49	The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e166-e173.	1.8	8
50	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1624-1632.	1.2	0
51	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 701668.	2.2	13
52	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 8908-8915.	0.7	4
53	ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer-A Multi-cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 688.	0.7	0
54	Reducing tumor invasiveness by ramucirumab and TGF α 2 receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model. <i>Cancer Medicine</i> , 2021, 10, 7253-7262.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
56	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021, 13, 11.	3.6	17
57	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	10
58	Analysis of inpatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1047.	0.3	2
59	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. <i>Journal of Clinical Oncology</i> , 2021, 39, 164-164.	0.8	21
60	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. <i>Cancers</i> , 2021, 13, 59.	1.7	8
61	409â€¦Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. , 2021, 9, A440-A440.		0
62	The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 792340.	1.3	3
63	Evorpcept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1740-1751.	5.1	46
64	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
65	Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. <i>European Journal of Surgical Oncology</i> , 2020, 46, 189-194.	0.5	10
66	A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. <i>Oncologist</i> , 2020, 25, e186-e193.	1.9	10
67	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 243-250.	1.4	16
68	Correlation between RICTOR overexpression and amplification in advanced solid tumors. <i>Pathology Research and Practice</i> , 2020, 216, 152734.	1.0	6
69	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Medicine</i> , 2020, 161, 105853.	1.3	23
70	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. <i>Targeted Oncology</i> , 2020, 15, 67-73.	1.7	1
71	Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. <i>Genome Medicine</i> , 2020, 12, 80.	3.6	134
72	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020, 6, 1461-1471.	0.8	44

#	ARTICLE	IF	CITATIONS
73	Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1976-1988.	3.2	53
74	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020, 152, 19-25.	0.3	9
75	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	1.4	9
76	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1059-1067.	1.9	2
77	IL-7R ^{hi} low CD8 ⁺ T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. <i>Journal of Immunology</i> , 2020, 205, 2968-2978.	0.4	5
78	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	3.4	611
79	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	8
80	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With <i>BRAF</i> ^{V600} Mutation—Positive Malignancies. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 651-658.	0.8	3
81	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	0.4	26
82	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	3.9	9
83	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. <i>Frontiers in Oncology</i> , 2020, 10, 225.	1.3	7
84	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	0.8	55
85	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). <i>Translational Cancer Research</i> , 2020, 9, 3222-3230.	0.4	3
86	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	1.0	6
87	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	7
88	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020, 216, 152881.	1.0	67
89	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. <i>Pathology Research and Practice</i> , 2020, 216, 152878.	1.0	21
90	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	3.6	20

#	ARTICLE	IF	CITATIONS
91	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020, 15, 185-192.	1.7	5
92	^{99m} Tc-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil. <i>PLoS ONE</i> , 2020, 15, e0228848.	1.1	4
93	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. <i>BMC Ophthalmology</i> , 2020, 20, 19.	0.6	32
94	Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. <i>JAMA Network Open</i> , 2020, 3, e203652.	2.8	19
95	CDH1 mutations in gastric cancers are not associated with family history. <i>Pathology Research and Practice</i> , 2020, 216, 152941.	1.0	4
96	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000670.	2.0	17
97	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. <i>Cancers</i> , 2020, 12, 943.	1.7	5
98	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2825.	1.8	11
99	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	1.3	62
100	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i> -Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 222-232.	1.5	16
101	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , 2020, 15, 203-209.	1.7	3
102	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152947.	1.0	11
103	401â€¦Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , .		2
104	A phase I study of TGF- β 2 inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11557-11557.	0.8	6
105	A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3056-3056.	0.8	11
106	Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3503-3503.	0.8	12
107	Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i> -fusion positive (<i>NTRK</i> -fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	0.8	33
108	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4513-4513.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. Journal of Clinical Oncology, 2020, 38, 4523-4523.	0.8	9
110	Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (<i>MET</i>^{Amp/Ex14}).. Journal of Clinical Oncology, 2020, 38, 9510-9510.	0.8	21
111	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GE) cancer by line of therapy.. Journal of Clinical Oncology, 2020, 38, 430-430.	0.8	20
112	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. Cancer Research and Treatment, 2020, 52, 1153-1161.	1.3	9
113	Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.. Journal of Clinical Oncology, 2020, 38, e22011-e22011.	0.8	0
114	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. Journal of Clinical Oncology, 2020, 38, e16541-e16541.	0.8	0
115	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. Journal of Clinical Oncology, 2020, 38, e16537-e16537.	0.8	1
116	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 4540-4540.	0.8	6
117	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 712-712.	0.8	5
118	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	0.8	0
119	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	0.8	0
120	288â€¦A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , .		0
121	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. OncoTargets and Therapy, 2019, Volume 12, 225-231.	1.0	4
122	Baseline neutrophilâ€™lymphocyte ratio and plateletâ€™lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori, 2019, 105, 434-440.	0.6	36
123	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. BMC Cancer, 2019, 19, 805.	1.1	9
124	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research, 2019, 25, 7035-7045.	3.2	152
125	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. Journal of Cancer, 2019, 10, 3172-3178.	1.2	9
126	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. Journal of Cancer, 2019, 10, 3140-3144.	1.2	5

#	ARTICLE	IF	CITATIONS
127	Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. <i>Scientific Reports</i> , 2019, 9, 9675.	1.6	7
128	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019, 9, 1388-1405.	7.7	155
129	<i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	1.9	16
130	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (â‰¥45 Years) With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 5811-5820.	0.5	6
131	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 15365.	1.6	54
132	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 6986-6994.	1.3	37
133	Anti-leukemic effects of simvastatin on NRASG12D mutant acute myeloid leukemia cells. <i>Molecular Biology Reports</i> , 2019, 46, 5859-5866.	1.0	12
134	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. <i>Translational Oncology</i> , 2019, 12, 1488-1495.	1.7	6
135	Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. <i>Scientific Reports</i> , 2019, 9, 14039.	1.6	125
136	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	1.7	8
137	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 612-622.	1.2	9
138	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 152434.	1.0	22
139	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. <i>PLoS ONE</i> , 2019, 14, e0215080.	1.1	2
140	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	0.9	26
141	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019, 9, 212.	1.3	20
142	Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. <i>Scientific Reports</i> , 2019, 9, 4542.	1.6	40
143	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	1.2	7
144	Bridging genomics and phenomics of gastric carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2407-2417.	2.3	40

#	ARTICLE	IF	CITATIONS
145	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
146	Acral malignant melanoma; emphasis on the primary metastasis and the usefulness of preoperative ultrasound for sentinel lymph node metastasis. Scientific Reports, 2019, 9, 15894.	1.6	2
147	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. Frontiers in Oncology, 2019, 9, 1327.	1.3	5
148	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. Journal of Cancer, 2019, 10, 6185-6190.	1.2	7
149	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. Scientific Reports, 2019, 9, 19439.	1.6	8
150	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	1.5	1
151	MET is overexpressed in microsatellite instability-high gastric carcinoma. Pathology Research and Practice, 2019, 215, 433-438.	1.0	10
152	Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient. Cancer Genetics, 2019, 231-232, 54-61.	0.2	1
153	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 501-508.	1.1	6
154	A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. Journal of Clinical Oncology, 2019, 37, 2514-2514.	0.8	15
155	Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.. Journal of Clinical Oncology, 2019, 37, 3000-3000.	0.8	40
156	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. Journal of Clinical Oncology, 2019, 37, 3104-3104.	0.8	2
157	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. Journal of Clinical Oncology, 2019, 37, 4001-4001.	0.8	53
158	Safety and preliminary clinical activity of repotrectinib in patients with advanced <i>ROS1</i> fusion-positive non-small cell lung cancer (TRIDENT-1 study).. Journal of Clinical Oncology, 2019, 37, 9011-9011.	0.8	58
159	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein-Barr virus positive gastric cancer.. Journal of Clinical Oncology, 2019, 37, e15509-e15509.	0.8	1
160	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. Journal of Clinical Oncology, 2019, 37, 66-66.	0.8	17
161	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	1.3	12
162	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer Research and Treatment, 2019, 51, 1128-1134.	1.3	12

#	ARTICLE	IF	CITATIONS
163	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	1.3	8
164	FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape. <i>Journal of Clinical Oncology</i> , 2019, 37, 72-72.	0.8	1
165	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 213-213.	0.8	0
166	Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling. <i>Journal of Clinical Oncology</i> , 2019, 37, 4064-4064.	0.8	0
167	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. <i>Journal of Clinical Oncology</i> , 2019, 37, 3046-3046.	0.8	0
168	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3023-3023.	0.8	3
169	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. <i>Translational Cancer Research</i> , 2019, 8, 2107-2112.	0.4	0
170	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4508-4515.	0.0	4
171	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 838-848.	1.9	36
172	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF ^{V600} Mutation-Positive Metastatic Malignancy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1067-1073.	1.0	11
173	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. <i>ESMO Open</i> , 2018, 3, e000326.	2.0	52
174	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 140-146.	1.0	17
175	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , 2018, 9, 1777.	5.8	245
176	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, 165-169.	1.0	71
177	Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. <i>Annals of Surgical Oncology</i> , 2018, 25, 1616-1624.	0.7	17
178	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018, 11, 353-357.	1.7	8
179	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 37-48.	7.7	248
180	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. <i>Translational Oncology</i> , 2018, 11, 37-42.	1.7	35

#	ARTICLE	IF	CITATIONS
181	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	1.0	17
182	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1198-1206.	0.6	6
183	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018, 18, 1103.	1.1	25
184	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	0.9	12
185	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018, 9, 3394-3399.	1.2	5
186	Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma. <i>Yonsei Medical Journal</i> , 2018, 59, 28.	0.9	15
187	Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. <i>Scientific Reports</i> , 2018, 8, 13887.	1.6	10
188	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. <i>Journal of Cancer</i> , 2018, 9, 3032-3037.	1.2	22
189	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018, 9, 1791-1796.	1.2	7
190	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 306-312.	0.3	12
191	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e3.	1.0	13
192	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	15.2	1,071
193	Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 524.	0.6	9
194	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	7.7	321
195	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	0.9	11
196	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018, 9, 2910-2915.	1.2	6
197	TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy. <i>Tumor Biology</i> , 2018, 40, 101042831879421.	0.8	6
198	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018, 50, 979-989.	9.4	168

#	ARTICLE	IF	CITATIONS
199	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Gastric Cancer</i> , 2018, 21, 1064-1070.	2.7	25
200	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). <i>Journal of Clinical Oncology</i> , 2018, 36, 2513-2513.	0.8	15
201	Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 4031-4031.	0.8	11
202	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatred gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 4061-4061.	0.8	3
203	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients. <i>Journal of Clinical Oncology</i> , 2018, 36, e14501-e14501.	0.8	1
204	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial. <i>Journal of Clinical Oncology</i> , 2018, 36, e16029-e16029.	0.8	1
205	Prediction of clinical outcomes for early gastric cancer using radiomic signatures derived from the quantitative texture analysis of conventional CT scans and machine learning. <i>Journal of Clinical Oncology</i> , 2018, 36, e16091-e16091.	0.8	1
206	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , 2018, 50, 175-182.	1.3	18
207	Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects. <i>Journal of Clinical Oncology</i> , 2018, 36, 10054-10054.	0.8	0
208	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type. <i>Journal of Clinical Oncology</i> , 2018, 36, e24234-e24234.	0.8	0
209	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases. <i>Journal of Clinical Oncology</i> , 2018, 36, 4063-4063.	0.8	0
210	Detection of targetable fusions using FusionPlex in oncology patients. <i>Journal of Clinical Oncology</i> , 2018, 36, e24238-e24238.	0.8	0
211	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Journal of Clinical Oncology</i> , 2018, 36, e16024-e16024.	0.8	0
212	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 170-175.	0.5	39
213	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	7.7	647
214	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 782-790.	1.2	22
215	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017, 10, 469-475.	1.7	23
216	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017, 17, 211.	1.1	24

#	ARTICLE	IF	CITATIONS
217	Gastric adenocarcinoma. Nature Reviews Disease Primers, 2017, 3, 17036.	18.1	409
218	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	183
219	Integrated genomic analyses reveal frequent <i>TERT</i> aberrations in acral melanoma. Genome Research, 2017, 27, 524-532.	2.4	122
220	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. Translational Oncology, 2017, 10, 304-310.	1.7	4
221	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	7.7	48
222	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncoimmunology, 2017, 6, e1356150.	2.1	32
223	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist, 2017, 22, 1169-1177.	1.9	14
224	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449.	3.2	342
225	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nature Communications, 2017, 8, 1377.	5.8	137
226	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Molecular and Clinical Oncology, 2017, 7, 27-31.	0.4	15
227	TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC. Tumor Biology, 2017, 39, 101042831770015.	0.8	5
228	3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor. Oncotarget, 2017, 8, 36484-36491.	0.8	8
229	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. Journal of Cancer, 2017, 8, 730-736.	1.2	1
230	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). Journal of Cancer, 2017, 8, 1395-1399.	1.2	20
231	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2017, 8, 2809-2815.	1.2	18
232	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. Journal of Cancer, 2017, 8, 2713-2719.	1.2	16
233	Acquired resistance to LY2874455 in <i>FGFR2</i> -amplified gastric cancer through an emergence of novel <i>FGFR2-ACSL5</i> fusion. Oncotarget, 2017, 8, 15014-15022.	0.8	42
234	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology, 2017, 1, 1-15.	1.5	31

#	ARTICLE	IF	CITATIONS
235	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	0.8	21
236	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
237	Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4067-4067.	0.8	10
238	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15610-e15610.	0.8	1
239	Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans. <i>PLoS ONE</i> , 2017, 12, e0185826.	1.1	10
240	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	0.8	20
241	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017, 8, 13320-13328.	0.8	60
242	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. <i>Oncotarget</i> , 2017, 8, 42478-42486.	0.8	32
243	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017, 8, 73974-73980.	0.8	5
244	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 107492-107499.	0.8	9
245	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017, 8, 66305-66315.	0.8	23
246	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017, 8, 105727-105734.	0.8	16
247	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	0.8	23
248	IKK μ and TBK1 expression in gastric cancer. <i>Oncotarget</i> , 2017, 8, 16233-16242.	0.8	11
249	Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 217-226.	0.7	5
250	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017, 49, 44-53.	1.3	27
251	Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.. <i>Journal of Clinical Oncology</i> , 2017, 35, 589-589.	0.8	0
252	Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 47-47.	0.8	3

#	ARTICLE	IF	CITATIONS
253	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	0.8	0
254	Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity.. Journal of Clinical Oncology, 2017, 35, e23068-e23068.	0.8	0
255	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. Journal of Clinical Oncology, 2017, 35, e15686-e15686.	0.8	0
256	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. Journal of Clinical Oncology, 2017, 35, 4024-4024.	0.8	1
257	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget, 2016, 7, 10547-10556.	0.8	52
258	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. Journal of Cancer, 2016, 7, 1044-1048.	1.2	17
259	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. Journal of Cancer, 2016, 7, 2173-2178.	1.2	1
260	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. Journal of Cancer, 2016, 7, 1174-1180.	1.2	25
261	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Cancer Research and Treatment, 2016, 48, 553-560.	1.3	19
262	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 104-111.	1.8	12
263	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. Journal of Gastric Cancer, 2016, 16, 105.	0.9	34
264	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget, 2016, 7, 43492-43503.	0.8	45
265	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology, 2016, 151, 637-650.e10.	0.6	127
266	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Translational Oncology, 2016, 9, 557-564.	1.7	16
267	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Modern Pathology, 2016, 29, 1095-1103.	2.9	70
268	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Translational Oncology, 2016, 9, 173-178.	1.7	22
269	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. Molecular Diagnosis and Therapy, 2016, 20, 375-383.	1.6	13
270	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Translational Oncology, 2016, 9, 197-202.	1.7	10

#	ARTICLE	IF	CITATIONS
271	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , 2016, 16, 120.	1.1	35
272	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36
273	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	1.2	30
274	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. <i>ESMO Open</i> , 2016, 1, e000009.	2.0	16
275	Clinical Significance of Mucinous Rectal Adenocarcinoma following Preoperative Chemoradiotherapy and Curative Surgery. <i>Tumori</i> , 2016, 102, 114-121.	0.6	9
276	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016, 6, 8.	2.3	10
277	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	1.2	11
278	Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. <i>Clinical Cancer Research</i> , 2016, 22, 3831-3840.	3.2	99
279	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016, 24, 301-309.	1.0	11
280	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 76-81.	0.9	12
281	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—A feasibility analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11534-11534.	0.8	3
282	Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2502-2502.	0.8	5
283	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2570-2570.	0.8	4
284	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4009-4009.	0.8	42
285	Prognostic value of the metastatic lymph node (N) ratio in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4038-4038.	0.8	1
286	Correlation between PD-L1 expression and PD-1 immune checkpoint blockade: A retrospective analysis for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21007-e21007.	0.8	1
287	Integrated genomic analyses identify frequent gene fusion events and <i>VHL</i> inactivation in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 6538-6551.	0.8	29
288	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. <i>Oncotarget</i> , 2016, 7, 4024-4035.	0.8	36

#	ARTICLE	IF	CITATIONS
289	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , 2016, 7, 19610-19619.	0.8	12
290	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 24088-24096.	0.8	15
291	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 34-44.	0.7	10
292	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	1.3	11
293	Early, molecular detection of cancer utilizing circulating cell-free DNA assay with ultra high accuracy and sensitivity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11540-11540.	0.8	0
294	Ipilimumab real-world efficacy and safety in Asian melanoma patients from the Korean Named-Patient Program cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21002-e21002.	0.8	0
295	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15628-e15628.	0.8	0
296	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4091-4091.	0.8	0
297	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15153-e15153.	0.8	0
298	Moving molecular subtypes to the clinic in gastric cancer. <i>Translational Cancer Research</i> , 2016, 5, S25-S30.	0.4	1
299	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. <i>Scientific Reports</i> , 2015, 5, 9289.	1.6	43
300	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring <i>KIT</i> Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015, 20, 1312-1319.	1.9	70
301	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015, 8, 288-294.	1.7	8
302	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015, 15, 693.	1.1	23
303	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	1.1	10
304	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015, 6, 40360-40369.	0.8	85
305	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , 2015, 10, e0140712.	1.1	580
306	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	0.7	25

#	ARTICLE	IF	CITATIONS
307	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	0.8	57
308	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015, 8, 40-46.	1.7	16
309	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	6.1	197
310	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 3130-3136.	0.8	370
311	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015, 21, 449-456.	15.2	1,592
312	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015, 15, 530.	1.1	17
313	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	1.1	58
314	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 171-177.	0.3	31
315	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	0.8	2
316	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) - Final overall and subgroup results. <i>Journal of Clinical Oncology</i> , 2015, 33, 4003-4003.	0.8	11
317	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid) Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, e12540-e12540.	0.8	1
318	Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type. <i>PLoS ONE</i> , 2015, 10, e0137657.	1.1	21
319	Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun. <i>Oncotarget</i> , 2015, 6, 20190-20203.	0.8	29
320	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	0.8	32
321	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	0.8	48
322	The NEXT-1 (Next generation personalized tx with multi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	0.8	24
323	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015, 6, 40026-40035.	0.8	15
324	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	0.8	53

#	ARTICLE	IF	CITATIONS
325	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 4268.	1.4	8
326	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 738-746.	1.3	10
327	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4049-4049.	0.8	2
328	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3576.	0.8	3
329	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN [®] .. <i>Journal of Clinical Oncology</i> , 2015, 33, e22173-e22173.	0.8	0
330	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11010-11010.	0.8	0
331	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22241-e22241.	0.8	0
332	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	1.9	34
333	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 13.	2.3	28
334	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 561-568.	1.2	2
335	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. <i>Nature Communications</i> , 2014, 5, 5477.	5.8	166
336	The analysis of mutations and exon deletions at <i>TSC2</i> gene in angiomyolipomas associated with tuberous sclerosis complex. <i>Experimental and Molecular Pathology</i> , 2014, 97, 440-444.	0.9	5
337	Simvastatin plus capecitabine+ cisplatin versus placebo plus capecitabine+ cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014, 50, 2822-2830.	1.3	79
338	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. <i>Investigational New Drugs</i> , 2014, 32, 535-541.	1.2	30
339	Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling. <i>Scientific Reports</i> , 2014, 4, 3623.	1.6	25
340	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014, 4, 7592.	1.6	24
341	Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 158-158.	0.8	1
342	Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. <i>PLoS ONE</i> , 2014, 9, e103551.	1.1	21

#	ARTICLE	IF	CITATIONS
343	High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. PLoS ONE, 2014, 9, e111693.	1.1	34
344	Pulmonary metastasectomy for colorectal cancer: How many nodules, how many times?. World Journal of Gastroenterology, 2014, 20, 6133.	1.4	60
345	Aggressive clinical course of extramammary Paget disease after radiotherapy. Radiation Oncology Journal, 2014, 32, 95.	0.7	5
346	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 447-56.	0.6	25
347	Ultra-high-quality sequencing assay for comprehensive genetic panel analysis of tumor-derived circulating cell-free DNA in colorectal cancer patients.. Journal of Clinical Oncology, 2014, 32, 504-504.	0.8	18
348	The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.. Journal of Clinical Oncology, 2014, 32, 10586-10586.	0.8	1
349	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. Journal of Clinical Oncology, 2014, 32, 4008-4008.	0.8	1
350	Evaluation of biochemical features of anemia in cancer patients.. Journal of Clinical Oncology, 2014, 32, e20698-e20698.	0.8	1
351	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics and Proteomics, 2014, 11, 259-66.	1.0	25
352	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. Anticancer Research, 2014, 34, 6585-91.	0.5	2
353	High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histology and Histopathology, 2014, 29, 127-38.	0.5	30
354	Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer, 2013, 119, 1627-1635.	2.0	108
355	Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer. PLoS ONE, 2013, 8, e82770.	1.1	36
356	Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology, 2013, 31, 3608-3608.	0.8	3
357	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 492-492.	0.8	1
358	Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma. Cancer Research and Treatment, 2013, 45, 285-294.	1.3	12
359	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. Journal of Clinical Oncology, 2013, 31, e15613-e15613.	0.8	0
360	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. Discovery Medicine, 2013, 15, 333-41.	0.5	14

#	ARTICLE	IF	CITATIONS
361	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. <i>Discovery Medicine</i> , 2013, 16, 7-14.	0.5	13
362	A comparative study of telomerase activity and cytologic diagnosis in malignant ascites. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013, 35, 146-51.	0.2	4
363	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 268-273.	0.8	667
364	Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 181-188.	5.1	407
365	Statins and the risk of gastric cancer in diabetes patients. <i>BMC Cancer</i> , 2012, 12, 596.	1.1	48
366	Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene. <i>PLoS ONE</i> , 2012, 7, e34456.	1.1	28
367	High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e38892.	1.1	72
368	Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4011-4011.	0.8	8
369	Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10535-10535.	0.8	1
370	A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13044-e13044.	0.8	0
371	A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14072-e14072.	0.8	0
372	Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. <i>Oncology Reports</i> , 2011, 25, 1517-24.	1.2	111
373	Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations. <i>Journal of the National Cancer Institute</i> , 2011, 103, 674-688.	3.0	87
374	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. <i>Korean Journal of Pathology</i> , 2011, 45, 276.	1.2	0
375	Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 657-663.	1.1	69
376	Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. <i>Apmis</i> , 2009, 117, 598-606.	0.9	41
377	A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 77-84.	1.1	38
378	Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1356-1364.	2.0	133

#	ARTICLE	IF	CITATIONS
379	Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 82-88.	3.2	40
380	Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type. <i>Clinical Cancer Research</i> , 2007, 13, 3250-3254.	3.2	48
381	Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. <i>Cancer</i> , 2007, 109, 1561-1569.	2.0	120
382	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 359-364.	0.4	41
383	Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 47-52.	1.1	34
384	Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study. <i>Blood</i> , 2007, 110, 1361-1361.	0.6	0
385	Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 612-618.	0.8	560
386	Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 339, 748-754.	1.0	58
387	Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells. <i>Oncology Reports</i> , 2006, 15, 1541-9.	1.2	16
388	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. <i>International Journal of Hematology</i> , 2005, 81, 258-263.	0.7	6
389	Curcumin inhibits interferon- α induced NF- κ B and COX-2 in human A549 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 313-318.	1.0	56
390	Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , 2005, 41, 1402-1408.	1.3	152
391	Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Thoracic Surgery</i> , 2005, 80, 1170-1175.	0.7	59
392	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma. <i>Blood</i> , 2005, 106, 1491-1491.	0.6	0
393	Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. <i>Leukemia and Lymphoma</i> , 2004, 45, 339-344.	0.6	50
394	Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic Cancer. <i>Oncology</i> , 2004, 66, 32-37.	0.9	20
395	Tuberculosis in Hematopoietic Stem Cell Transplant Recipients in Korea. <i>International Journal of Hematology</i> , 2004, 79, 185-188.	0.7	36
396	Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 385-390.	1.1	83

#	ARTICLE	IF	CITATIONS
397	A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 3162-3162.	0.6	1
398	Clinical Characteristics of Takayasu's Arteritis. Sunhwan'gi, 2001, 31, 1106.	0.3	6
399	Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 1970, 47, 72-77.	1.3	20
400	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. Journal of Gynecologic Oncology, 0, 29, .	1.0	0